Main Products/ Services/ Pipelines & Platforms
MAIN PRODUCTS (MINC Platform technology) Suntec’s MINC (Multi-target Immune-modulation Nanocomplex) platform develops combination drugs for cancer, CNS, autoimmune and vaccines with the benefits of: • Alzheimer’s/Parkinson’s: 1) retards disease progression, 2) promotes neural cell viability, 3) restores cognitive behavior, 4) reduces death rate • Vaccine: 1) stabilizes RNA/DNA for 4-25 ℃ storage, 2) higher antibody titer • Cancer: 1) removes ADR, 2) tumor targeting, 3) boosts patient immunity PIPELINES • Drug candidates(11) for cancers(4), Alzheimer’s(6) and Parkinson’s(1). • Three drugs(STM-001, 002, 003) are IND ready in 2023. • FDA "breakthrough" designation potentials and long IP protections (18-19 yrs).
Business Interests
• Out-license: Out-license STM-001, 002, 003. • Co-development: All pipeline drugs are open to co-development. • Fund raising: Series A fundraising to support human trials • Custom-formulation: Formulate client’s drugs using MINC technology.
Contact Info
Isaac Cheng
Vice President, Research
+886-909-277-680
isaac.cheng@suntecmedical.com